Cancer Immunology Research

Article	Citations
Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy	150
A Sampling of Highlights from the Literature	100
Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy	96
Imaging α-GalCer–Activated iNKT Cells in a Hepatic Metastatic Environment	94
KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2–CXCL10 Axis in Colorectal Cancer	88
Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti–PD-1 in Metastatic Non–Small Cell Lung Cancer	80
Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions	77
Acknowledgment to Reviewers	71
Abstract P042: Chemokine dysregulation creates the immunosuppressive tumor microenvironment and promotes human papillomavirus-associated head and neck cancer	70
A Sampling of Highlights from the Literature	56
CD59-Regulated Ras Compartmentalization Orchestrates Antitumor T-cell Immunity	54
All Glioblastoma Are Not Equal: Distinct Spatial Immune Profiles BetweenDe Novoand Recurrent Tumors	52
HIF1α or HIF2α: Enhancing CD8+ T-cell Fitness for Antitumor Immunity	51
Abstract PO091: Armed Myxoma virus demonstrates efficacy in syngeneic tumor models alone and in combination with immune checkpoint inhibitors	51
Discovery of Podofilox as a Potent cGAMP–STING Signaling Enhancer with Antitumor Activity	50
VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation	49
Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells	47
CLN-617 Retains IL2 and IL12 in Injected Tumors to Drive Robust and Systemic Immune-Mediated Antitumor Activity	47
Low Serum Apolipoprotein A1 Levels Impair Antitumor Immunity of CD8+ T Cells via the HIF-1α–Glycolysis Pathway	47
Intracellular Osteopontin Promotes the Release of TNFα by Mast Cells to Restrain Neuroendocrine Prostate Cancer	46
Abstract PO010: The inhibition of IWS1 phosphorylation promotes genomic instability, the cGAS/STING pathway activation and PD-L1 levels, through the U2AF2 alternative RNA splicing and Sororin expressi	45
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer	44
CD161 Characterizes an Inflamed Subset of Cytotoxic T Lymphocytes Associated with Prolonged Survival in Human Papillomavirus–Driven Oropharyngeal Cancer	43
Long-Read Sequencing Reveals Alternative Splicing-Driven, Shared Immunogenic Neoepitopes Regardless of SF3B1 Status in Uveal Melanoma	43
Abstract PO019: CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer	43

LEF1 Drives a Central Memory Program and Supports Antitumor Activity of Natural Killer T Cells	42
The Conventional Dendritic Cell 1 Subset Primes CD8+ T Cells and Traffics Tumor Antigen to Drive Antitumor Immunity in the Brain	42
Reciprocal Interactions Between the Gut Microbiome and Mammary Tissue Mast Cells Promote Metastatic Dissemination of HR+ Breast Tumors	42
A Sampling of Highlights from the Literature	40
A Sampling of Highlights from the Literature	38
Exercise as an Immune Boost: Mechanism-Driven Support for Lifestyle Interventions	38
Martin A. “Mac” Cheever, MD: In Memoriam (1944–2021)	38
Accounting for B-cell Behavior and Sampling Bias Predicts Anti–PD-L1 Response in Bladder Cancer	38
A Sampling of Highlights from the Literature	37
Tumor-Associated High Endothelial Venules: Inroads Enabling Immune Control of Cancer Progression	37
A Sampling of Highlights from the Literature	36
Abstract IA16: Discovery of new immunotherapy targets and mechanisms leveraging CRISPR	36
Abstract PO020: Anti-membrane-IgM monoclonal antibody, mAb4, inhibits the BCRC, modulating downstream signaling pathways	35
Abstract PO012: A subset of monocyte-derived macrophages in glioblastoma multiforme supports antitumor immune responses	35
Abstract IA05: Innate immune defenses against cancer: Potential for mobilizing NK cells for cancer immunotherapy	35
Abstract IA02: A case for priming, not checkpoint	35
Abstract PO015: Tumor-cell-intrinsic epigenetic factors underlie the heterogeneity of immune infiltration and response to immunotherapy in pancreatic cancer	35
Abstract PR002: Highly parallel knock-in targeting for genome engineering of cellular therapies	34
Abstract PO056: The kinetics of the anti-glioblastoma immune response in immunocompetent mouse models is influenced by neglected factors	34
Abstract PO062: Isolation of tumor-infiltrating lymphocytes for higher sensitivity gene expression profiling	34
Abstract PO092: Multi-region sequencing analysis of metastatic solid tumors to inform targeting of personalized cancer immunotherapies	33
Abstract PO079: Effects of the lung tumor microenvironment on T cell therapy	33
Abstract PO077: BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized 4-1BB agonism	33
Abstract PO016: Single-cell analyses characterize circulating anti-tumor CD8 T cells and identify markers for their isolation	33
Abstract P046: NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer	32
Abstract PO049: Enhancement of anticancer efficacy of PD1 blockade by combining with a polysaccharide PG2 isolated from Huang Qi	32
Abstract P033: Bone microenvironment-suppressed T cells increase osteoclast formation and the development of osteolytic bone metastases in mice	32
Abstract PR008: Armed Myxoma virus demonstrates therapeutic activity in pre-clinical xenograft models	32
Abstract P003: Efficacy results of a novel vaccine composed of stimulated and haptenized tumors cells in Balbc mice grafted with murine colon adenocarcinoma CT26 cells	32
Abstract P074: MB097: A therapeutic consortium of bacteria clinically-defined by precision microbiome profiling of immune checkpoint inhibitor patients with potent anti-tumor efficacy in vitro and in	31
Abstract PR08: Context is everything: Microbiota-specific T follicular helper cells in colorectal cancer	30
Abstract P013: Germinal center hypoxia in tumor-draining lymph nodes negatively regulates humoral immune responses and affects the activation of tumor-infiltrating T cells	30
Abstract IA06: Chimeric antigen receptor macrophages for the treatment of solid tumors	29
Abstract P039: The immune profile of colorectal and pancreas adenocarcinomas: Differences between central and peripheric tumor regions	29
Abstract PR05: Lymph node colonization promotes distant tumor metastasis through the induction of tumor-specific immune tolerance	29
Abstract P024: Using innate immune ligands to activate adaptive immune cells for glioblastoma therapy	28
Abstract P035: A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27	27
Abstract P061: Dendritic cell paucity in mismatch repair-proficient colorectal cancer liver metastases limits the efficacy of immune checkpoint blockade	27
Abstract P031: Enrichment of photodynamically-primed anti-tumor immune infiltrates in pancreatic cancer: Enabling enhanced immunotherapy	26
Abstract P018: Gut microbiota-driven alterations in tumor immunity can modulate the growth of metastatic brain tumors	26
Abstract IA21: Understanding responses to cancer therapy: The tissue is the issue, the scoop is in the poop, and you are what you eat	26
Abstract P070: The safety and efficacy of Durvalumab and Paclitaxel combination in metastatic triple-negative breast cancer: An open-label phase I/II trial with 2-years follow-up	25
Revival and Recharacterization of a Preclinical Model of Hormone-Dependent Breast Cancer to Study Immunotherapy	25
Rationally Designed Transgene-Encoded Cell-Surface Polypeptide Tag for Multiplexed Programming of CAR T-cell Synthetic Outputs	25
CD4+ Regulatory T Cells in Human Cancer: Subsets, Origin, and Molecular Regulation	24
Repertoire Remodeling through CD4+ T-cell Depletion	24
Dual Chimeric Antigen Receptor T Cells Targeting CD38 and SLAMF7 with Independent Signaling Demonstrate Preclinical Efficacy and Safety in Multiple Myeloma	24
Abstract P028: Effects of histone deacetylase inhibition on major histocompatibility compatibility complex (MHC) class I expression, growth, and migration of cancer cells	24
Regional Variation in the Tumor Microenvironment, Immune Escape and Prognostic Factors in Breast Cancer in Sub-Saharan Africa	24
A Sampling of Highlights from the Literature	24

Metabolic Screening of Cytotoxic T-cell Effector Function Reveals the Role of CRAC Channels in Regulating Lethal Hit Delivery	23
TIGIT-Fc Promotes Antitumor Immunity	23
Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer	23
Clec4A4 Acts as a Negative Immune Checkpoint Regulator to Suppress Antitumor Immunity	23
Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR	22
Abstract P053: Ablation of CCR1 relieves immunosuppression in pancreatic cancer	22
Acute Influenza Infection Promotes Lung Tumor Growth by Reprogramming the Tumor Microenvironment	21
Lessons for the Next Generation of Scientists from the Second Annual Arthur and Sandra Irving Cancer Immunology Symposium	21
Antigen Priming Induces Functional Reprogramming in iNKT Cells via Metabolic and Epigenetic Regulation: An Insight into iNKT Cell-Based Antitumor Immunotherapy	21
How to Reprogram Myeloma-Associated Macrophages: Target IKZF1	21
Sequential Exposure to IL21 and IL15 During Human Natural Killer Cell Expansion Optimizes Yield and Function	21
Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade	21
Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment	20
T-cell Therapies Targeting Multiple Cancer Antigens: The Power of Many	20
The ω-3 Polyunsaturated Fatty Acid Docosahexaenoic Acid Enhances NK-Cell Antitumor Effector Functions	20
Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner	20
Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma	20
Flightless I Homolog Reverses Enzalutamide Resistance through PD-L1–Mediated Immune Evasion in Prostate Cancer	20
Abstract IA11: Viral vectored vaccines for prostate cancer	20
Abstract IA22: Immunotherapy for melanoma: Checkpoint blockade combinations	20
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers	20
Intratumoral Gene Transfer of mRNAs Encoding IL12 in Combination with Decoy-Resistant IL18 Improves Local and Systemic Antitumor Immunity	19
Host Interactions with Engineered T-cell Micropharmacies	19
LEF1 Creates Memories in iNKT Cells That Potentiate Antitumor Immunity	19
CD86+ Antigen-Presenting B Cells Are Increased in Cancer, Localize in Tertiary Lymphoid Structures, and Induce Specific T-cell Responses	19
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory	19
Tyrosine Kinase Inhibition Alters Intratumoral CD8+ T-cell Subtype Composition and Activity	19
Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies	18
cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1	18
CD8+ T–cell Immune Surveillance against a Tumor Antigen Encoded by the Oncogenic Long Noncoding RNA PVT1	18
Immune-Guided Therapy of COVID-19	18
Long Noncoding RNA MIR4435-2HG Suppresses Colorectal Cancer Initiation and Progression By Reprogramming Neutrophils	18
An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity	18
EDIL3 as an Angiogenic Target of Immune Exclusion Following Checkpoint Blockade	17
The Spatial Structure of the Tumor Immune Microenvironment Can Explain and Predict Patient Response in High-Grade Serous Carcinoma	17
Augmenting CAR T-cell Functions with LIGHT	17
Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies	17
ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses	17
A Single-Cell Analysis of the NK-Cell Landscape Reveals That Dietary Restriction Boosts NK-Cell Antitumor Immunity via Eomesodermin	17
Optimal Neoantigen Cancer Vaccines Target CD8+ and CD4+ T Cells with Multiple Antigens	17
Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling	17
Allogeneic CAR T Cells: Complex Cellular Therapy Designs Test the Limits of Our Preclinical Models	17
CD36+ Proinflammatory Macrophages Interact with ZCCHC12+ Tumor Cells in Papillary Thyroid Cancer Promoting Tumor Progression and Recurrence	17
Subcapsular Sinus Macrophages Promote Melanoma Metastasis to the Sentinel Lymph Nodes via an IL1α–STAT3 Axis	16
Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes	16
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects	16
PD-1/PD-L1–Associated Immunoarchitectural Patterns Stratify Pancreatic Cancer Patients into Prognostic/Predictive Subgroups	16
IL18 at the Crossroads between Chronic Inflammation and T-cell Exhaustion in Pancreatic Cancer	16
Intermittent MEK Inhibition with GITR Costimulation Rescues T-cell Function for Increased Efficacy with CTLA-4 Blockade in Solid Tumor Models	16
P. gingivalisInfection Upregulates PD-L1 Expression on Dendritic Cells, Suppresses CD8+ T-cell Responses, and Aggravates Oral Cancer	16
Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors	16
Gefitinib Reverses PD-L1–Mediated Immunosuppression Induced by Long-term Glutamine Blockade in Bladder Cancer	15
Adenosine A2a Receptor Antagonism Restores Additive Cytotoxicity by Cytotoxic T Cells in Metabolically Perturbed Tumors	15
A Population of TIM4+FOLR2+ Macrophages Localized in Tertiary Lymphoid Structures Correlates to an Active Immune Infiltrate Across Several Cancer Types	15
CD73 Inhibits cGAS–STING and Cooperates with CD39 to Promote Pancreatic Cancer	15
Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis	15
Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand–Expressing Solid Tumors	15
CD49a Targeting Enhances NK Cell Function and Antitumor Immunity	15
Targeting the Siglec–Sialic Acid Immune Axis in Cancer: Current and Future Approaches	15
The Tautomerase Activity of Tumor Exosomal MIF Promotes Pancreatic Cancer Progression by Modulating MDSC Differentiation	15
P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy	14
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy	14
Combination of Anti–PD-1 and Electroacupuncture Induces a Potent Antitumor Immune Response in Microsatellite-Stable Colorectal Cancer	14
Do Not Forget the Granulocytic Compartment’s Role in T cell–Mediated Antitumor Immunity	14
Netrin-1 Promotes the Immunosuppressive Activity of MDSCs in Colorectal Cancer	14
IL18 Receptor Signaling Regulates Tumor-Reactive CD8+ T-cell Exhaustion via Activation of the IL2/STAT5/mTOR Pathway in a Pancreatic Cancer Model	14
Targeting BTN2A1 Enhances Vγ9Vδ2 T-Cell Effector Functions and Triggers Tumor Cell Pyroptosis	14
Identification of Immunogenic MHC Class II Human HER3 Peptides that Mediate Anti-HER3 CD4+ Th1 Responses and Potential Use as a Cancer Vaccine	14
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression	14
The TOPK Inhibitor HI-TOPK-032 Enhances CAR T-cell Therapy of Hepatocellular Carcinoma by Upregulating Memory T Cells	14
Spatially Resolved Whole-Transcriptomic and Proteomic Profiling of Lung Cancer and Its Immune Microenvironment According to PD-L1 Expression	14
In situ detection of individual classical MHC-I gene products in cancer	13
Abstract P021: Highly multiplexed spatial analysis of the HCC tumor immune microenvironment using CODEX imaging	13
Preclinical Characterization of Relatlimab, a Human LAG-3–Blocking Antibody, Alone or in Combination with Nivolumab	13
PKCδ germline variants and genetic deletion in mice augment antitumor immunity through regulation of myeloid cells	13
Engineered T-cell Receptor T Cells for Cancer Immunotherapy	13
Transforming the Dark into Light: A Siglec-9 Switch	13
Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer	13
Abstract PO044: RTX-321, an allogeneic red blood cell-based artificial antigen presenting cell, expressing MHC I-peptide, 4-1BBL and IL-12, engages primary human HPV-specific T cells and boosts other	12
Engineering Principles for Synthetic Biology Circuits in Cancer Immunotherapy	12

A Sampling of Highlights from the Literature	12
Adaptable Leukemia Cells Resisting CAR T-cell Attack via B-cell Activation	12
Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects	12
Computational Quantification of Cancer Immunoediting	12
Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy	12
Neutrophils Mediate Protection Against Colitis and Carcinogenesis by Controlling Bacterial Invasion and IL22 Production by γδ T Cells	12
Low TCR Binding Strength Results in Increased Progenitor-like CD8+ Tumor-Infiltrating Lymphocytes	12
A Sampling of Highlights from the Literature	12
The Tumor Microenvironment of Clear-Cell Ovarian Cancer	12
T-cell Receptor Gene Therapy Clinically Targeting aTP53Public Neoantigen	12
A Sampling of Highlights from the Literature	12
High Mobility Group Protein B1 Decreases Surface Localization of PD-1 to Augment T-cell Activation	12
Ethnicity, Immunity, and Outcomes: Biology versus Socioeconomic Status	11
Lung cancer–intrinsic SOX2 expression mediates resistance to checkpoint blockade therapy by inducing Treg cell–dependent CD8+ T-cell exclusion	11
Linking a Trio of Molecular Features in Clear-Cell Renal Cell Carcinoma	11
Tertiary lymphoid structures in pancreatic cancer are structurally homologous, share gene expression patterns and B-cell clones with secondary lymphoid organs but show increased T-cell activation	11
Phosphoantigen-Stimulated γδ T Cells Suppress Natural Killer–Cell Responses to Missing-Self	11
Systemic Alterations in Type-2 Conventional Dendritic Cells Lead to Impaired Tumor Immunity in Pancreatic Cancer	11
About the Rising Star	11
Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy	11
Ncoa2 Promotes CD8+ T cell–Mediated Antitumor Immunity by Stimulating T-cell Activation via Upregulation of PGC-1α Critical for Mitochondrial Function	10
Infiltration of Tumors Is Regulated by T cell–Intrinsic Nitric Oxide Synthesis	10
A Sampling of Highlights from the Literature	10
Ursula Grohmann, PhD: In Memoriam (1961–2022)	10
A Metabolic Gene Survey Pinpoints Fucosylation as a Key Pathway Underlying the Suppressive Function of Regulatory T Cells in Cancer	10
Engineering CD20 CARs with a Twist	10
A γδ T–cell Imprint in a Rare Skin Tumor	10
A Sampling of Highlights from the Literature	10
MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2	10
Galectin-1 Supports a Dangerous Liaison between Monocytes and Multiple Myeloma	10
Reversing Imatinib's Immunosuppressive Effects by Modulating Type I IFN Signaling	10
A Sampling of Highlights from the Literature	9
Abstract IA08: What are some different ways to evaluate immunotherapy combinations?	9
Abstract PR01: Oncolytic adenoviruses expressing metabolic targets can improve viro-immunotherapy with bispecific T cell engagers through reducing acidosis in an in vitro model	9
Abstract IA17: The power of ONE: Immunology in the age of single cell genomics	9
CRASH-IT Switch Enables Reversible and Dose-Dependent Control of TCR and CAR T-cell Function	9
Abstract PO076: Development of a CD137 (4-1BB) receptor occupancy assay using fluorescently labelled Bicycles®	9
Abstract IA05: CAR NK Cells: The future of cancer immunotherapy	9
Abstract PO067: The immune cell infiltration and landscape predicts clinical outcomes in gynecologic cancers	9
Hiroshi Shiku, MD, PhD: In Memoriam (1943–2022)	9
Abstract P060: Identification of host-intrinsic resistance mechanisms to immune checkpoint inhibitors (ICI) in Diversity Outbred mice	9
Abstract IA16: Immune suppression in cancer and strategies for its reversal	9
Abstract PO042: Oncostatin M receptor as a therapeutic target of radioimmune therapy in metastatic synovial sarcoma	8
Abstract P048: Steatosis promote liver cancer development by inducing chemokine production from Kupffer cells	8
Abstract P073: Gut microbiota shift in melanoma patients undergoing immunotherapy is associated with clinical response	8
Abstract P009: Correlation between immune modulation of macrophage recruitment and new blood vessel formation in a subcutaneous murine mouse model of colorectal cancer	8
Abstract PO060: Biomarkers Diverging between Tumor Mutation Burden and Microsatellite Instability	8
Abstract P062: PI3Kγδ inhibitor plus radiation enhances the antitumor immune effect of PD-1 blockade in syngenic murine breast cancer and humanized patient-derived xenograft model	8
Abstract P064: Dual effect of epigenetic inhibitor and CAR-NK cell therapy in bladder cancer	8
Abstract P065: Effects of targeted radiotherapy on tumor immune landscape in diverse murine tumor models	8
Abstract IA15: Targeting tumor associated macrophages for anti-cancer therapy	8
Abstract PO022: Somatic mutations in tumor infiltrating lymphocytes can affect the expression of immune system genes in the tumor microenvironment	8
Abstract P008: Effect of route of Bacillus Calmette Guérin administration on the tumor immune microenvironment in a mouse model of non-muscle invasive bladder cancer	8
Abstract IA08: Adaptive immune dysregulation in cancer patients with SARS-CoV-2 infection	8
Abstract P022: Reciprocal influence of immune response and tumor hypoxia during glioblastoma progression	8
Abstract PO002: APOBEC mutagenesis as a driver of tumor evolution by promoting tumor recurrence and modulating tumor-immune system interactions in a syngeneic murine model of breast cancer	8